Oncology Institute's (TOI) Buy Rating Reaffirmed at BTIG Research

Key Points

• BTIG Research has reaffirmed a "buy" rating for Oncology Institute (NASDAQ:TOI), setting a target price of $7.00, indicating a potential upside of 65.09% from its previous close.
• In recent insider trading, Director Growth I. L.P. M33 sold over 6 million shares, representing a nearly 43.14% decrease in their position.
• Institutional investors currently own 36.86% of the company's stock, with several recent investments, including significant new positions from WealthShield Partners LLC and Goldman Sachs Group Inc.

Oncology Institute (NASDAQ:TOI - Get Free Report)'s stock had its "buy" rating restated by investment analysts at BTIG Research in a research note issued on Tuesday,Benzinga reports. They presently have a $7.00 target price on the stock. BTIG Research's target price suggests a potential upside of 65.09% from the company's previous close.

A number of other research firms have also issued reports on TOI. B. Riley began coverage on Oncology Institute in a research note on Wednesday, July 16th. They issued a "buy" rating and a $6.00 target price for the company. Noble Financial began coverage on Oncology Institute in a research note on Wednesday, July 23rd. They issued an "outperform" rating and a $8.00 target price for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Oncology Institute in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $7.00.

Oncology Institute Stock Performance

Shares of NASDAQ:TOI opened at $4.24 on Tuesday. The firm has a market capitalization of $396.46 million, a PE ratio of -6.24 and a beta of 0.08. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.62 and a quick ratio of 1.37. The business has a 50-day moving average of $3.56 and a two-hundred day moving average of $3.07. Oncology Institute has a 12 month low of $0.13 and a 12 month high of $4.50.

Insider Buying and Selling

In other Oncology Institute news, Director Growth I. L.P. M33 sold 6,018,168 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $3.09, for a total transaction of $18,596,139.12. Following the transaction, the director owned 7,932,389 shares of the company's stock, valued at $24,511,082.01. This trade represents a 43.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 8.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. XTX Topco Ltd grew its stake in Oncology Institute by 49.5% during the 1st quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock worth $63,000 after buying an additional 18,448 shares during the last quarter. WealthShield Partners LLC bought a new position in Oncology Institute during the 1st quarter worth $80,000. Citizens Financial Group Inc. RI bought a new position in Oncology Institute during the 1st quarter worth $71,000. Josh Arnold Investment Consultant LLC bought a new position in Oncology Institute during the 1st quarter worth $2,267,000. Finally, Goldman Sachs Group Inc. bought a new position in Oncology Institute during the 1st quarter worth $131,000. Institutional investors own 36.86% of the company's stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.